- Pear Therapeutics ( NASDAQ: PEAR ) has signed an agreement with COEUS Healthcare to utilize the latter's outcomes and evidence-based reimbursement adjudication platform, COEBRA, to enable value-based contracting .
- The pact will facilitate states' access to value-based contracting to use Pear's ( PEAR ) prescription digital therapeutics ("PDT").
- PDTs are cognitive behavioral therapy-based treatments used as an adjunct to other therapies.
- Pear ( PEAR ) currently markets reSET and reSET-O, PDTs for, respectively, substance use disorder and opioid use disorder.
- Earlier in January, Pear ( PEAR ) extended an agreement with Spero Health , an outpatient opioid treatment provider.
For further details see:
Pear to use COEUS Healthcare value-based contracting for prescription digital therapeutics